Skip to contentR
Relay Therapeutics, Inc.
R
RLAYRelay Therapeutics, Inc. Q1 2022 · 10-Q
Revenue$419.00K$419.00K−56.0% vs Q1 2021 Net Income-$62.05M-$62.05MN/M vs Q1 2021 EPS Diluted-$0.57-$0.57N/M vs Q1 2021 Operating Income-$62,721,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Relay Therapeutics, Inc. · CIK 1812364 · Engraved from SEC EDGAR
Free Cash Flowderived-$51,967,000N/M Margins · derivedOperating margin-14969.2%−10514.9 pt vs Q1 2021
Net margin-14808.1%−10377.0 pt vs Q1 2021
ended Mar 31, 2022 · filed May 5, 2022 · 35 d after period end